GlassScriptPhysician profile
Stephanie Tsai
NPI 1013144260
$160,440.16
in general payments reported to CMS, 2019-2025
16 companies · $42K in 2025
The $42K reported for 2025 was more than what 92% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $2,200 · 2021: $12K · 2022: $42K · 2023: $26K · 2024: $26K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Consulting Fee: $11K · Travel and Lodging: $10K · Food and Beverage: $2,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $70,494.00 |
| Consulting Fee | $10,826.00 |
| Travel and Lodging | $10,458.21 |
| Food and Beverage | $2,280.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $47,831.72 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $40,293.11 | 2022-2024 | Onureg |
| Gamida Cell INC. | $33,613.63 | 2025 | Omisirge, Aphexda |
| Sanofi-Aventis U.S. LLC | $25,386.65 | 2024-2025 | |
| Celgene Corporation | $6,445.97 | 2021-2024 | |
| Servier Pharmaceuticals LLC | $5,913.72 | 2022 | |
| Abbvie INC. | $300.00 | 2025 | |
| Genzyme Corporation | $254.83 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $204.42 | 2019-2025 | |
| Syndax Pharmaceuticals, INC. | $99.56 | 2025 | Revuforj |
| Kite Pharma, INC. | $50.00 | 2024 | |
| Incyte Corporation | $46.55 | 2025 | Jakafi, Niktimvo |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.